BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Fengyun WangMing LuoHonglan QuYufeng ChengPublished in: FEBS open bio (2021)
More than 40 000 patients worldwide die from esophageal cancer annually. The 5-year survival rate of patients is only ~ 15-20%, and thus, there is an ongoing need to improve diagnosis and treatment of esophageal cancer. Breast cancer type 1 susceptibility protein (BRCA1)-associated protein (BAP1) is a marker of poor prognosis in several cancers, including uveal melanoma, renal cell carcinoma, cholangiocarcinoma, non-small cell lung cancer, and colorectal cancer. BAP1 mutations are early and rare events in esophageal carcinoma, but the involvement of BAP1 in progression of esophageal carcinoma is unclear. Here, we report that cell proliferation and migration were significantly enhanced in esophageal carcinoma ECA109 cells overexpressing BAP1, while they were diminished upon BAP1 knockdown. In addition, the expression of Krüppel-like factor 5 (KLF5), CyclinD1, and FGF-BP1 was increased by BAP1 overexpression and decreased by BAP1 knockdown. Our data suggest that BAP1 promotes cell proliferation and migration, and enhances the expression of KLF5 and its downstream genes, including CyclinD1 and FGF-BP1, in the esophageal carcinoma cell line ECA109.
Keyphrases
- poor prognosis
- end stage renal disease
- ejection fraction
- long non coding rna
- induced apoptosis
- newly diagnosed
- transcription factor
- renal cell carcinoma
- peritoneal dialysis
- prognostic factors
- cell cycle arrest
- single cell
- cell therapy
- stem cells
- patient reported outcomes
- binding protein
- cell death
- machine learning
- gene expression
- endoplasmic reticulum stress
- signaling pathway
- electronic health record
- mesenchymal stem cells
- artificial intelligence
- free survival